Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis

Infection and Immunity

Volumn 73, Issue 2, 2005, Pages 812-819

  Aguilar Be, Ingrid ^a   Da Silva Zardo, Renata ^b   De Souza, Edilma Paraguai ^b   Borja Cabrera, Gulnara Patrícia ^b   Rosado Vallado, Miguel ^a   Mut Martin, Mirza ^a   García Miss, Maria Del Rosario ^a   Palatnik De Sousa, Clarisa Beatriz ^b   Dumonteil, Eric ^a  

^a UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DNA VACCINE; FUCOSE; LIGAND; MANNOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELL PROTECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNE RESPONSE; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTECTION; PROTOZOAL INFECTION; SKIN LEISHMANIASIS; T LYMPHOCYTE ACTIVATION; TH1 CELL; VACCINATION; VISCERAL LEISHMANIASIS; WOUND HEALING;

ANIMALS; IMMUNITY, CELLULAR; LECTINS; LEISHMANIA DONOVANI; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MICE; TIME FACTORS; VACCINES, DNA;

EID: 12844258219     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.2.812-819.2005     Document Type: Article

References (58)

1. Alexander, J., and J. M. Blackwell. 1986. The immunological significance of genetically determined cross reactivity between taxonomically distinct Leishmania species, p. 185-191. In J. A. Rioux (ed.), Leishmania, taxonomie et phylogenèse: application éco-épidemiologiques. Institut Méditerranéen d'Etudes Epidémiologiques et Ecologiques, Montpellier, France.
2. Alexander, J., and R. S. Phillips. 1978. Leishmania tropica and Leishmania mexicana: cross-immunity in mice. Exp. Parasitol. 45:93-100.
3. Barral, A., R. Badaro, M. Barral-Netto, G. Grimaldi, Jr., H. Moment, and E. M. Carvalho. 1986. Isolation of Leishmania mexicana amazonensis from the bone marrow in a case of American visceral leishmaniasis. Am. J. Trop. Med. Hyg. 35:732-734.
4. Bebars, M. A., A. O. el Serougi, K. M. Makled, E. M. Mikhael, M. M. Abou Gamra, M. el Sherbiny, A. W. Mohareb, and E. A. Mohammed. 2000. An experimental vaccine providing heterologous protection for Leishmania species in murine model. J. Egypt. Soc. Parasitol. 30:137-156.
5. Borja-Cabrera, G. P., N. N. Correia Pontes, V. O. da Silva, E. Paraguai de Souza, W. R. Santos, E. M. Gomes, K. G. Luz, M. Palatnik, and C. B. Palatnik de Sousa. 2002. Long-lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN). Vaccine 20:3277-3284.
6. Borja-Cabrera, G. P., A. Cruz Mendes, E. Paraguai de Souza, L. Y. Hashimoto Okada, F. A. de Trivellato, J. K. Kawasaki, A. C. Costa, A. B. Reis, O. Genaro, L. M. Batista, M. Palatnik, and C. B. Palatnik-de-Sousa. 2004. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 22:2234-2243.
7. Borja-Cabrera, G. P., V. O. Da Silva, R. T. Da Costa, A. B. Reis, W. Mayrink, O. Genaro, and C. B. Palatnik-de-Sousa. 1999. The fucose-mannose ligand-ELISA in the diagnosis and visceral leishmaniasis in Brazil. Am. J. Trop. Med. Hyg. 61:296-301.
8. Campbell, K., H. Diao, J. Ji, and L. Soong. 2003. DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous leishmaniasis. Infect. Immun. 71:6270-6278.
9. Campos-Neto, A., J. R. Webb, K. Greeson, R. N. Coler, Y. A. Skeiky, and S. G. Reed. 2002. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect. Immun. 70:2828-2836.
10. Canto-Lara, S., M. F. Cardenas-Maruffo, A. Vargas-Gonzalez, and F. Andrade-Narvaez. 1998. Isozyme characterization of Leishmania isolated from human cases with localized cutaneous leishmaniasis from the state of Campeche, Yucatan Peninsula, Mexico. Am. J. Trop. Med. Hyg. 58:444-447.
11. Colmenares, M., S. Kar, K. Goldsmith-Pestana, and D. McMahon-Pratt. 2002. Mechanisms of pathogenesis: differences amongst Leishmania species. Trans. R. Soc. Trop. Med. Hyg. 96(Suppl. 1):S3-S7.
12. Cui, L., G. R. Rajasekariah, and S. K. Martin. 2001. A nonspecific nucleoside hydrolase from Leishmania for purine salvage by the parasite. Gene 280:153-162.
13. da Silva, V. O., G. P. Borja-Cabrera, N. N. Correia Pontes, E. P. de Souza, K. G. Luz, M. Palatnik, and C. B. Palatnik de Sousa. 2000. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN). Vaccine 19:1082-1092.
14. Desjeux, P. 1992. Human leishmaniases: epidemiology and public health aspects. World Health Stat. Quart. 45:267-275.
15. Dumonteil, E., D. McMahon-Pratt, and V. Price. 2001. Report on the fourth TDR/IDRI meeting on second-generation vaccines against leishmaniasis, 1 to 3 May 2001. Universidad Autonoma de Yucatan, Yucatan, Mexico. Document TDR/PDR/LEISH/VAQ01.1.
16. Dumonteil, E., M. J. Ramirez-Sierra, J. Escobedo-Ortegon, and M. R. Garcia-Miss. 2003. DNA vaccines induce partial protection against Leishmania mexicana. Vaccine 21:2161-2168.
17. Gicheru, M. M., J. O. Olobo, and C. O. Anjili. 1997. Heterologous protection by Leishmania donovani for Leishmania major infections in the vervet monkey model of the disease. Exp. Parasitol. 85:109-116.
18. Gopaul, D. N., S. L. Meyer, M. Degano, J. C. Sacchettini, and V. L. Schramm. 1996. Inosine-uridine nucleoside hydrolase from Crithidia characterization, crystallization, and identification of a catalytic site residue. Biochem. 35:5963-5970.
19. Gurunathan, S., C. Prussin, D. L. Sacks, and R. A. Seder. 1998. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4:1409-1415.
20. Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glaichenhaus, and R. A. Seder. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1137-1147.
21. + T cells. J. Immunol. 165:915-924.
22. Hernandez, D. E., N. Rodriguez, M. Wessolossky, and J. Convit. 1995. Visceral leishmaniasis due to a Leishmania variant that shares kinetoplast DNA sequences with Leishmania braziliensis and Leishmania mexicana in a patient infected with human immunodeficiency virus: identification of the Leishmania species with use of the polymerase chain reaction. Clin. Infect. Dis. 21:701-702.
23. Hernandez-Montes, O., A. Monroy-Ostria, S. McCann, and D. C. Barker. 1998. Identification of Mexican Leishmania species by analysis of PCR amplified DNA. Acta Trop. 71:139-153.
24. Hu, J,. R. Han, N. M. Cladel, M. D. Pickel, and N. D. Christensen. 2002. Intracutaneous DNA vaccination with the E8 gene of cottontail rabbit papillomavirus induces protective immunity against virus challenge in rabbits. J. Virol. 76:6453-6459.
25. Khalil, E. A., A. M. El Hassan, E. E. Zijlstra, M. M. Mukhtar, H. W. Ghalib, B. Musa, M. E. Ibrahim, A. A. Kamil, M. Elsheikh, A. Babiker, and F. Modabber. 2000. Autoclaved Leishmania major vaccine for prevention of leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356:1565-1569.
26. Lainson, R., and J. J. Shaw. 1977. Leishmaniasis in Brazil: XII. Observations on cross-immunity in monkeys and man infected with Leishmania mexicana mexicana, L. m. amazonensis, L. braziliensis braziliensis, L. b. guyanensis and L. b, panamensis. J. Trop. Med. Hyg. 80:29-35.
27. Lima, H. C., G. K. DeKrey, and R. G. Titus. 1999. Resolution of an infection with Leishmania brasiliensis confers complete protection to a subsequent challenge with Leishmania major in BALB/c mice. Mem. Inst. Oswaldo Cruz 94:71-76.
28. Mauricio, I. L., J. R. Stothard, and M. A. Miles. 2000. The strange case of Leishmania chagasi. Parasitol. Today 16:188-189.
29. Melby, P. C., J. Yang, W. Zhao, L. E. Perez, and J. Cheng. 2001. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69:4719-4725.
30. Mendez, S., S. Gurunathan, S. Kamhawi, Y. Belkaid, M. A. Moga, Y. A. Skeiky, A. Campos-Neto, S. Reed, R. A. Seder, and D. Sacks. 2001. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol. 166:5122-5128.
31. Miller, R. L., C. L. Sabourin, T. A. Krenitsky, R. L. Berens, and J. J. Marr. 1984. Nucleoside hydrolases from Trypanosoma cruzi. J. Biol. Chem. 259:5073-5077.
32. Monroy-Ostria, A., O. Hernandez-Montes, and D. C. Barker. 2000. Aetiology of visceral leishmaniasis in Mexico. Acta Trop. 75:155-161.
33. Okongo-Odera, E. A., E. S. Mitema, D. K. Koech, and A. S. Orago. 1995. Cross-reactive studies in visceral leishmaniasis: comparison of antigens of some Leishmania species in Kenya. Afr. J. Health Sci. 2:304-308.
34. Olobo, J. O., C. O. Anjili, M. M. Gicheru, P. A. Mbati, T. M. Kariuki, J. I. Githure, D. K. Koech, and W. R. McMaster. 1995. Vaccination of vervet monkeys against cutaneous leishmaniasis using recombinant Leishmania "major surface glycoprotein" (gp63). Vet. Parasitol. 60:199-212.
35. Palatnik, C. B., R. Borojevic, J. O. Previato, and L. Mendonca-Previato. 1989. Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate ligands. Infect. Immun. 57:754-763.
36. Palatnik, C. B., J. O. Previato, L. Mendonca-Previato, and R. Borojevic. 1990. A new approach to the phytogeny of Leishmania: species specificity of glycoconjugate ligands for promastigote internalization into murine macrophages. Parasitol. Res. 76:289-293.
37. Palatnik de Sousa, C. B., M. M. Bunn Moreno, E. Paraguai de Souza, and R. Borojevic. 1994. Vaccination with the FML antigen (fucose-mannose ligand) of Leishmania donovani protects hamsters from experimental visceral leishmaniasis. J. Bras. Soc. Adv. Sci. 46:290-296.
38. Palatnik de Sousa, C. B., E. M. Gomes, E. Paraguai de Souza, M. Palatnik, K. Luz, and R. Borojevic. 1995. Leishmania donovani: titration of antibodies to the fucose-mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 89:390-393.
39. Palatnik de Sousa, C. B., E. M. Gomes, E. Paraguai de Souza, W. R. Santos, S. R. Macedo, L. V. Medeiros, and K. G. Luz. 1996. The FML (fucose-mannose ligand) of Leishmania donovani: a new tool in diagnosis, prognosis, transfusional control, and vaccination against human kala-azar. Rev. Soc. Bras. Med. Trop. 29:153-163.
40. Paraguai de Souza, E., R. R. Bernardo, M. Palatnik, and C. B. Palatnik de Sousa. 2001. Vaccination of BALB/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine 19:3104-3115.
41. Passos, V. M., O. Fernandes, P. A. Lacerda, A. C. Volpini, C. M. Gontijo, W. Degrave, and A. J. Romanha. 1999. Leishmania (Viannia) braziliensis is the predominant species infecting patients with American cutaneous leishmaniasis in the State of Minas Gerais, Southeast Brazil. Acta Trop. 72:251-258.
42. Pelle, R., V. L. Schramm, and D. W. Parkin. 1998. Molecular cloning and expression of a purine-specific N-ribohydrolase from Trypanosoma brucci brucei: sequence, expression, and molecular analysis. J. Biol. Chem. 273:2118-2126.
43. Rachamim, N., and C. L. Jaffe. 1993. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 150:2322-2331.
44. + T lymphocyte activation. Vaccine 20:2439-2447.
45. Rafati, S., A. F. Salmanian, T. Taheri, M. Vafa, and N. Fasel. 2001. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 19:3369-3375.
46. Ramos-Santos, C., O. Hernandez-Montes, G. Sanchez-Tejeda, and A. Monroy-Ostria. 2000. Visceral leishmaniasis caused by Leishmania mexicana in a Mexican patient with human immunodeficiency virus infection. Mem. Inst. Oswaldo Cruz 95:733-737.
47. Sanchez-Tejeda, G., N. Rodriguez, C. I. Parra, O. Hernandez-Montes, D. C. Barker, and A. Monroy-Ostria. 2001. Cutaneous leishmaniasis caused by members of Leishmania braziliensis complex in Nayarit, State of Mexico. Mem. Inst. Oswaldo Cruz 96:15-19.
48. Santana, D. M., G. P. Borja-Cabrera, E. Paraguai de Souza, N. R. Sturm, C. B. Palatnik de Sousa, and D. A. Campbell. 2002. Nucleoside hydrolase from Leishmania donovani is an antigen diagnostic for visceral leishmaniasis. Mol. Biochem. Parasitol. 120:315-319.
49. Santos, W. R. 2002. Effect of the FML-vaccine on the tegumentar and visceral experimental murine leishmaniaisis: comparative ananlysis of adjuvants, p. 123-128. Ph.D. thesis. Institute de Microbiologia "Prof. Paulo de Goes," Universidad Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
50. Santos, W. R., V. M. de Lima, E. P. de Souza, R. R. Bernardo, M. Palatnik, and C. B. Palatnik de Sousa. 2002. Saponins, IL-12, and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 21:30-43.
51. Santos, W. R., E. Paraguai de Souza, M. Palatnik, and C. B. Palatnik de Sousa. 1999. Vaccination of Swiss albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani. Vaccine 17:2554-2561.
52. Seder, R. A., and A. V. S. Hill. 2000. Vaccine against intracellular infections requiring cellular immunity. Nature 406:793-798.
53. Sepulveda, P., M. Hontebeyrie, P. Liegeard, A. Mascilli, and K. A. Norris. 2000. DNA-Based immunization with Trypanosoma cruzi complement regulatory protein elicits complement lytic antibodies and confers protection against Trypanosoma cruzi infection. Infect. Immun. 68:4986-4991.
54. Silva, C. L., V. L. Bonato, V. M. Lima, L. H. Faccioli, and S. C. Leao. 2002. Characterization of the memory/activated T cells that mediate the long-lived host response against tuberculosis after bacillus Calmette-Guerin or DNA vaccination. Immunol. 97:573-581.
55. Sjolander, A., T. M. Baldwin, J. M. Curtis, K. L. Bengtsson, and E. Handman. 1998. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine 16:2077-2084.
56. Sjolander, A., T. M. Baldwin, J. M. Curtis, and E. Handman. 1998. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J. Immunol. 160:3949-3957.
57. Stobie, L., S. Gurunathan, C. Prussin, D. L. Sacks, N. Glaichenhaus, C. Y. Wu, and R. A. Seder. 2000. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc. Natl. Acad. Sci. USA 97:8427-8432.
58. Xu, D., and F. Y. Liew. 1995. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of Leishmania major. Immunology 84:173-176.